

PUBLICATIONS

1. Foster H, Hooper M, Imann S H, Lovett G S, Nicholson J, Swain C J, Sweetman A J, Weetman D F. (1983) Biological Activities of Isatogens Brit. J. Pharm., 79, 273.
2. Baker R, Bhaskar Rao V, Ravenscroft P D, Swain C J. (1983) Oxidation of Trimethylsilyl ethers. Synthesis, 572 (1983).
3. Baker R, Bayes R H O, Broom D M P, Devlin J A, Swain C J. (1983) The Chemistry of Spiroacetals: Enantiospecific synthesis of the spiroacetal unit of Milbemycin B₃. J. Chem. Soc. Chem. Commun, 829.
4. Baker R, Ravenscroft P D, Swain C J. (1984) The total synthesis of Ancistrofuran. J. Chem. Soc. Chem. Commun. 74.
5. Baker R, Gibson C L, Swain C J, Tapolczay D J. (1984) Synthetic studies on Paniculides. J. Chem. Soc. Chem. Commun. 619.
6. Baker R, O'Mahony M J, Swain C J. (1984) The total synthesis of Wintermoth Pheromone. J. Chem. Res. 190.
7. Baker R, Head J C, Swain C J. (1985) The Chemistry of Spiroacetals: Enantiospecific Synthesis of the spiroacetal unit of Avermectin B_{1b} and B_{2b}. J. Chem. Soc. Chem. Commun. 309.
8. Baker R, Swain C J, Head J. (1985) Recent Advances in the Chemistry of Insect Control. Ed. N.F. Jones, Pub. The Royal Society of Chemistry. p.245.
9. Baker R, Gibson C L, Swain C J, Tapolczay D J. (1985) Synthetic studies on the Paniculides. J. Chem Soc. Perk I, 1590.
10. Baker R, Cotterell I F, Ravenscroft P D, Swain C J. (1985) The total synthesis of Ancistrofuran. J. Chem. Soc. Perk I, 2463.
11. Baker R, O'Mahony M J, Swain C J. (1985) The total synthesis of (+) Milbemycin β₃. J. Chem. Soc. Chem. Commun., 1326.
12. Baker R, Head J C, Swain C J. (1985) Chemistry of Spiroacetals, Enantiospecific synthesis of the spiroacetal units of milbemycins a₇ and a₈. J. Chem. Soc. Chem. Commun., 874.
13. Hooper M, Adams D B, Swain C J, Raper E S, Stoddart B. (1986) Isatogens: X-ray crystal structure. J. Chem. Soc. Perk. I, 1005.
14. Swain C J, Baker R, O'Mahony. (1986) A formal synthesis of Milbemycin B₃. Tetrahedron Lett. 27, 3059.
15. Baker R, Boyes R H O, Broom D M P, O'Mahony M J, Swain C J. (1987) Enantiospecific synthesis of the spiroacetal unit of Milbemycin B₃. J. Chem. Soc. Perkin Trans 1, 1613.
16. Baker R, O'Mahony M J, Swain C J. (1987) The total synthesis of (+) Milbemycin B₃. J. Chem. Soc. Perkin Trans. 1, 1623.
17. Baker R, Head J C, Swain C J. (1988) Synthesis of spiroacetals. J. Chem. Soc. Perkin Trans 1., 85.
18. Castro J L, Baker R, Swain C J. (1988) Directed Aldol Chemistry.

Tet. Lett. 29 (18) 2247.

19. Watling K J, Aspley S, Swain C J, Saunders J. (1988) Radioligand binding assay for 5-HT₃ antagonists. Eur. J. Pharmac. 149, 397.
20. Baker R, Boyes A L, Swain C J. (1989) The total synthesis of Talaromycins A,B,C and E. Tet. Lett, 30 (8) 985.
21. Baker R, Swain C J. Ivermectin - a drug for all seasons. Chem. in Brit., 692.
22. Watgen F, Baker R, Engelstoff M, Herbert R, MacLeod A, Knight A, Merchant K, Moseley J, Saunders J, Swain C J, Wong E, Springer J P. (1989) Novel Benzodiazepine Receptor Partial Agonists: Oxadiazolyimidazobenzodiazepines. J. Med. Chem.. 32, 2282.
23. Swain C J, Kneen C, Baker R. (1990) Synthesis of Indole Oxazolines, Potent 5-HT₃ antagonists. Tet. Lett. 31, 2445.
24. Baker R, Boyes A L, Swain C J. (1990) Synthesis of Talaromycins A, B, C and E. J. Chem. Soc. Perkin Trans 1., 1415.
25. McKernan R M, Gillard N P, Quirk K, Kneen C O, Stevenson G I, Swain C J, Ragan C I. (1990) Purification of the 5-HT₃ receptor from NCB20 cells. J. Biol. Chem. 265 (23), 13572.
26. Swain C J, Kneen C, Herbert R, Baker R. (1990) Synthesis of Indole Oxazolines: Novel 5-HT₃ antagonists. J. Chem. Soc. Perkin Trans 1 3183.
27. Swain C J, Baker R, Kneen C, Moseley J, Saunders J, Seward E M, Stevenson G, Beer M, Stanton J, Watling K. (1991) Novel 5-HT₃ Antagonists. Indole Oxadiazoles. J. Med. Chem. 34, 140.
28. Booth S E, Jenkins P R, Swain C J. (1991) The Synthesis of Bicyclic and Tricyclic Ring Systems by Radical Cyclisation Reactions of Oxime ethers. J. Chem Soc. Chem. Commun. 1248.
29. Tattersall D, Newberry N, Beer M, Rigby M, Gilbert M, Maquire J, Mudunotuwa N, Duchonowski M, McKnight A, Swain C J, Kneen C, Dourish C. (1992) L-683,877: Pharmacological Profile of a Novel 5-HT₃ Receptor Antagonist. Drug Development Research, 25, 25, 17.
30. Swain C J, Baker R, Kneen C, Herbert R, Moseley J, Saunders J, Seward E M, Stevenson G I, Beer M, Stanton J, Watling K, Ball R G. (1992) Novel 5-HT₃ Antagonists: Indol-3-ylspiro(azabicycloalkane-3,5¹(4¹H)-oxazoles). J Med. Chem., 35, 1019.
31. Cascieri M A, Ber E, Tung M F, Sadowski S, Bansal S, Swain C J, Seward E M, Frances B, Burns D, Strader C D. (1992) Characterization of the binding of a potent, selective, radioiodinated antagonist to the human neurokinin-1 receptor. Molecular Pharmacology, 42, 458-463.
32. Jenkins P, Symons M C R, Booth S E, Swain C J. (1992) Why is a vinyl anion configurationally stable but a vinyl radical configurationally unstable. Tet. Lett., 33, 3543.
33. Rajagopal S, Diksic M, Francis B, Swain C J, Burns H D. (1992) Synthesis of a ¹¹C-labeled novel, quinuclidine based ligand for the 5-HT₃ receptor. Applied Radiation and Isotopes, 43, 1369-1373,
34. Francis B E, Swain C J, Sabin V, Burns H D. Radioiodinated L-703,606:A Potent Selective Antagonist to the human NK₁ Receptor. Appl. Radiat. Isot.

35. Booth S E, Jenkins P R, Swain C J. (1993) A novel Ring expansion reaction in the reduction of Benzylic Methoxyamines with Lithium Aluminium Hydride. *J. Chem. Soc. Chem. Commun.*, 147.
36. Cascieri M A, Fong T M, Yu H, Bansai A, Swain C J, Strader C D. (1993). Amino-aromatic interaction between histidine 197 of the NK₁ receptor and CP 96345. *Nature*, 362, 350.
37. Seward E M, Swain C J, Merchant K J, Owen S N, Savin V, Cascieri M A, Sadowski S, Strader C D, Baker R. (1993) Quinuclidine Based NK₁ antagonists 1: 3-Benzoyloxy-1-azabicyclo[2.2.2]octanes. *Bioorganic and Med. Chem. Lett.*, 3, (6), 1361.
38. MacLeod A M, Merchant K J, Cascieri M A, Shadowski S, Ber E, Swain C J, Baker R. (1993) N-Acyl-L-Tryptophan Benzyl Esters: Potent Substance P antagonists. *J. Med. Chem.* 36, 2044.
39. Swain C J, Seward E M, Sabin V, Owen S, Baker R, Cascieri M A, Sadowski S, Strader C, Ball R G. (1993) Quinuclidine Based NK₁ Antagonists 2: Determination of the Absolute Stereochemical Requirements, *Bioorganic and Med. Chem. Lett.* 3 (8), 1703.
40. Fong T M, Yu H, Cascieri M A, Underwood D, Swain C J, Strader C D. (1994) The role of the Histidine 265 in Antagonist Binding to the NK₁ Receptor. *J. Biol. Chem.* 269 (4), 2728.
41. Cascieri M A, MacLeod A M, Underwood D, Shiao L, Ber E, Sadowski S, Yu H, Merchant K J, Swain C J, Strader C D, Fong T M. (1994) Characterization of the Interaction of N-Acyl-L-Tryptophan Benzyl Ester Neurokinin Antagonists with the human NK₁ receptor. *J. Biol. Chem.* 269 (9), 6587.
42. MacLeod A M, Merchant K J, Brookfield F, Kelleher F, Stevenson G, Owens A P, Swain C J, Cascieri M A, Sadowski S, Ber E, Strader C D, Macintyre D E, Metzger J M, Ball R G, Baker R. (1994) Identification of L-Tryptophan Derivatives with Potent and Selective Activity at the NK₁ receptor. *J. Med. Chem.* 37, 1269.
43. Fong T M, Yu H, Cascieri M A, Underwood D, Swain C J, Strader C D. (1994) Interaction of Glutamine 165 in the fourth Transmembrane Segment of the human NK₁ Receptor with Quinuclidine Receptor with Quinuclidine Antagonists. *J. Biol. Chem.* 269 (21) 14957.
44. Williams B J, Teall M, McKenna J, Harrison T, Swain C J, Cascieri M A, Sadowski S, Strader C D, Baker R. (1994) Acyclic NK₁ Antagonists: 2-Benzhydryl-2-aminoethyl ethers. *Bioorg. and Med. Chem. Lett.* 4, (16), 1903.
45. Swain C J, Cascieri M A, Owens A, Saari W, Sadowski S, Strader C, Teall M, Van Niel M B, Williams B J. (1994) Acyclic NK₁ antagonists: Replacement for the benzhydryl group. *Bioorganic and Med. Chem. Lett.* 4, (18), 2161.
46. Harrison T, Williams B J, Swain C J, Ball R G. (1994) Piperidine-Ether Based hNK₁ Antagonists 1: Determination of the Relative and Absolute Stereochemical Requirements. *Bioorganic and Med. Chem. Lett.* 4 (21), 2545.
47. Harrison T, Williams B J, Swain C J. (1994) Gem-Disubstituted Amino-ether Based Substance P antagonists. *Bioorganic and Med. Chem. Lett.* 4 (23), 2733.
48. Jenkins P R, Booth S E, Swain C J, Sweeny J B. (1994) Intramolecular Addition of Vinyl and Aryl radicals to Oxime ethers in the synthesis of Five, Six and Seven-membered Ring Systems. *J. Chem. Soc. Perkin Trans. 1.* 3499.

49. Longmore J, Swain C J, Hill R G. (1995) Neurokinin Receptors. Drug News and Perspectives. 8 (1), 5.
50. Cascieri M A, Shiao L, Mills S G, MacCoss M, Swain C J, Yu H, Ber E, Sadowski S, Wu M T, Strader C D, Fong T M. (1995) Characterisation of the Interaction of Diacylpiperazine Antagonists with the human NK₁ receptor: Identification of a Common Binding site for structurally Dissimilar Antagonists. Mol. Pharm. 47, 660.
51. Swain C J., Fong T M, Haworth K, Owen S N, Seward E M. (1995) Quinuclidine based NK₁ antagonists the role of the benzhydryl. Biorganic and Med. Chem. Lett. 5(12), 1261.
52. Fong T M, Ruey-Ruey C, Huang H Y, Swain C J, Underwood D, Cascieri M A, Strader C D. (1995) Mutational analysis of neurokinin receptor function. Cam. J. Physiol. Pharmacol. 73, 860.
53. Owens A P, Williams B J, Harrison T, Swain C J, Baker R, Sadowski S, Cascieri M A. (1995) Phenyl-Glycinol Based NK₁ receptor antagonists-Towards the minimum Pharmacophore, Bioorganic and Med. Chem. Lett. 5 (22), 2761.
54. Swain C J, Seward E M, Cascieri M A, Fong T M, Herbert R, MacIntyre D E, Merchant K J, Owen S, Owens A P, Sabin V, Teall M, Van Niel M B, Williams B J, Sadowski S, Strader C D, Ball R G, Baker R. (1995) Identification of a series of 3-Benzylloxy-1-azabicyclo[2.2.2]octane human NK₁ antagonists. J. Med. Chem. 38, 4793 .
55. Fong T M, Yu H, Huang R-R, , Swain C J, Underwood D, Cascieri M A, Strader C D, (1995) Mutational analysis of neurokinin receptor function, Can. J. Physiol. Pharmacol. 73, 860
56. Swain C J, (1996) Neurokinin Receptor Antagonists, Expert Opinion on Therapeutic Patents, 6 (4) 367.
57. Swain C J, (1996) Neurokinin Receptor Antagonists, Drug Discovery Today, 1 (6)
58. Ladduwahetty T, Swain C J, Keown L, Seward E M, Haworth K, Owen S, Chambers M, Baker R, Cascieri M A, Hargreaves R J, Iversen L L, MacIntyre D E, Metzger J M, Sadowski S, Shephard S, Strader C D, Tattersall F D, (1996) L-741,671: A potent orally active human NK₁ antagonist, J. Med. Chem. 39, 2907
59. Swain C J, Hargreaves R, J (1996) Neurokinin Receptor Antagonists, Annual Reports in Medicinal Chemistry, 31, chapter 12,) 111
60. Fong T M, Yu H, Huang R-R, Cascieri M A, Swain C J, (1996) Relative Contribution of Polar Interactions and Conformational Compatibility to the binding of Neurokinin-1 Receptor Antagonists, Molecular Pharmacology, 50, 1605
61. Tattersall F D, Rycroft W, Francis B, Pearce D, Merchant K, MacLeod A M, Ladduwahetty T, Keone L, Swain C, Baker R, Cascieri M, Ber E, Metzger J, MacIntyre D E, Hill R, Hargreaves R, (1996) Tachykinin NK₁ Receptor Antagonists act centrally to inhibit Emesis Induced by the chemotherapeutic agent Cisplatin in Ferrets Neuropharmacology, 35, 8, 1121.
62. Rupniak N M J, Tattersall F D, Williams A R, Rycroft W, Carlson E J, Cascieri M, Sadowski S, Ber E, Hale J, Mills S, MacCoss M, Seward E, Huscroft I, Owen S, Swain C J, Hill R G, Hargreaves R J, (1997) In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK₁ receptor antagonists, Eur J Pharmacol. 326, 201.
63. Swain C J, Williams B J, Baker R, Cascieri M A 1, Chicchi G 1, Forrest M 2, Herbert R, Keown L, Ladduwahetty T, Luell S, MacIntyre D E, Metzger J, Morton S, Owens A P, Sadowski S 1 and

- Watt A P. (1997) 3-Benzyloxy-2-Phenylpiperidine NK1 antagonists: The influence of alpha methyl substitution. *Bioorganic and Medchem Letters*, 7 (23), 2959.
64. Owens A P, Harrison T, Moseley J D, Swain C J, Sadowski S 1 and Cascieri M A. (1998) High Affinity Phenylglycinol-Based NK1 Antagonists. *Bioorganic and Medchem Letters*, 8 (1), 51.
65. Kramer M S, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek J J, Reines S A, Liu G, Snively D, Wyatt-Knowles E, Hale J J, Mills S G, MacCoss M, Swain C J, Harrison T, Hill R G, Hefti F, Scolnick E M, Cascieri M A, Chicchi G G, Sadowski S, Williams A R, Hewson L, Smith D, Carlson E J, Hargreaves R J and Rupniak N M J, (1998) Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors, *Science*, 281 1640
66. Swain C J, (1998) Neurokinin Receptor Antagonists, *Progress in Medicinal Chemistry* 35, 57
67. Harper S, Bilsand J, Young L, Bristow L, Boyce S, Mason G, Rigby M, Hewson L, Smith D, O'Donnell R, O'connor D, Hill R G, Evans D, Swain C, Williams B, Hefti F. (1998) Analysis of the neurotrophic effects of GPI-1046 on neuronal survival and regeneration in culture and in vivo, *Neuroscience* 88, 1, 257
68. Smith A L, Stevenson G I, Swain C J, Castro J L, (1998) Traceless Solid Phase Synthesis of 2,3-Disubstituted Indoles, *Tet. Lett.*, 39 8317.
69. Booth S E, Jenkins P R, Swain C J, (1998) The preparation and Intramolecular Radical Cyclisation Reactions of oxime ethers, *J. Braz. Chem. Soc.* 9, 4, 389.
70. Stevenson, G I.; Huscroft, I; MacLeod, A M.; Swain, C J.; Cascieri, M A.; Chicchi, G G.; Graham, M I.; Harrison, T; Kelleher, F J.; Kurtz, M; Ladduwahetty, T; Merchant, K J.; Metzger, J M.; MacIntyre, D. E.; Sadowski, S; Sohal, B; Owens, A P. (1998) 4,4-Disubstituted Piperidine High-Affinity NK1 Antagonists: Structure-Activity Relationships and in Vivo Activity, *J. Med. Chem*, 41, 23, 4623.
71. Harrison, T. Korsgaard, M. P. G.; Swain, C. J. Cascieri, M. A. Sadowski, S. Seabrook, G. R (1998) High affinity, selective neurokinin 2 and neurokinin 3 receptor antagonists from a common structural template, *Bioorg. Med. Chem. Lett.* 8, 11, 1343
72. Swain C J, Harper S, Pollack S, Smith R, Hefti F. (1998) Neurotrophic Factor Mimetics, *Rev. Exp Pharm.* 134, 281
73. Harper, S.; Bilsland, J.; Young, L.; Bristow, L.; Boyce, S.; Mason, G.; Rigby, M.; Hewson, L.; Smith, D.; O'Donnell, R.; O'Connor, D.; Hill, R. G.; Evans, D.; Swain, C.; Williams, B.; Hefti, F. (1998), Analysis of the neurotrophic effects of GPI-1046 on neuron survival and regeneration in culture and in vivo. *Neuroscience* 88(1), 257-267.
74. Hollingworth, G J.; Dinnell, K; Dickinson, L C.; Elliott, J M.; Kulagowski, J J.; Swain, C J.; Thomson, C G. (1999), A convenient method for the preparation of aryl cyclopropyl ethers from phenols. *Tetrahedron Lett.* 40(13), 2633-2636.
75. Seward, E. M.; Swain, C J. (1999) Neurokinin receptor antagonists. *Expert Opin. Ther. Pat.* 9(5), 571-582.
76. Swain C J, Rupniak N M J. (1999) Recent developments in Neurokinin Antagonists *Annual Reports in Medicinal Chemistry*
77. Harper S J; Saporito M S; Hewson L; Young L; Smith D; Rigby M; Jackson P; Curtis N; Swain C; Hefti F; Vaught J L; Sirinathsinghji D (2000) CEP-1347 increases ChAT activity in culture

and promotes cholinergic neurone survival following fimbria-fornix lesion. *Neuroreport*, 11(10), 2271-6.

78. Kulagowski J J; Curtis N R; Swain C J; Williams B J. (2001) Stereocontrolled syntheses of epimeric 3-aryl-6-phenyl-1-oxa-7-azaspiro(4.5)decane NK-1 receptor antagonist precursors. *Organic Letters*, 3(5), 667-70.
79. Cooper L C; Chicchi G G; Dinnell K; Elliott J M; Hollingworth G J; Kurtz M M; Locker K L; Morrison D; Shaw D E; Tsao K L; Watt A P; Williams A R; Swain C J (2001) 2-Aryl indole NK1 receptor antagonists: optimisation of indole substitution. *Bioorganic and Medicinal Chemistry Letters*, 11(9), 1233-6.
80. Dinnell K; Chicchi G G; Dhar M J; Elliott J M; Hollingworth G J; Kurtz M M; Ridgill M P; Rycroft W; Tsao K L; Williams A R; Swain C J. (2001) 2-Aryl indole NK1 receptor antagonists: optimisation of the 2-aryl ring and the indole nitrogen substituent. *Bioorganic and Medicinal Chemistry Letters*, 11(9), 1237-40
81. Shaw D; Chicchi G G; Elliott J M; Kurtz M; Morrison D; Ridgill M P; Szeto N; Watt A P; Williams A R; Swain C J (2001) 2-Aryl indole NK(1) antagonists: optimisation of the amide substituent *Bioorganic and Medicinal Chemistry Letters*, 11(23), 3031-4.
82. Harrison T; Owens A P; Williams B J; Swain C J; Williams A; Carlson E J; Rycroft W; Tattersall F D; Cascieri M A; Chicchi G G; Sadowski S; Rupniak N M; Hargreaves R J. (2001) An orally active, water-soluble neurokinin-1 receptor antagonist suitable for both intravenous and oral clinical administration. *Journal of Medicinal Chemistry*, 44(24), 4296-9
83. Maubach K A; Martin K; Chicchi G; Harrison T; Wheeldon A; Swain C J; Cumberbatch M J; Rupniak N M J; Seabrook G R. (2002) Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus. *Neuroscience*, 109(3), 609-17.
84. Elliott J M; Castro J L; Chicchi G G; Cooper L C; Dinnell K; Hollingworth G J; Ridgill M P; Rycroft W; Kurtz M M; Shaw D E; Swain C J; Tsao K-L; Yang L. (2002) 4,4-Disubstituted cyclohexylamine NK(1) receptor antagonists I. *Bioorganic and Medicinal Chemistry Letters*. 12(13), 1755-8
85. Cooper L C; Carlson E J; Castro J L; Chicchi G G; Dinnell K; Di Salvo J; Elliott J M; Hollingworth G J; Kurtz M M; Ridgill M P; Rycroft W; Tsao K-L; Swain C J. (2002) 4,4-Disubstituted cyclohexylamine NK(1) receptor antagonists II. (2002) *Bioorganic and Medicinal Chemistry Letters*, 12(13), 1759-62
86. Seward E M; Carlson E; Harrison T; Haworth K R; Herbert R; Kelleher F J; Kurtz M M; Moseley J; Owen S N; Owens A P; Sadowski S J; Swain C J; Williams B J. (2002) Spirocyclic NK(1) antagonists I: [4.5] and [5.5]-spiroketals. *Bioorganic and Medicinal Chemistry Letters*. 12(18), 2515-8
87. Conley R K; Cumberbatch M J; Mason G S; Williamson D J; Harrison T; Locker K; Swain C; Maubach K; O'Donnell R; Rigby M; Hewson L; Smith D; Rupniak N M J. (2002) Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity. *Journal of Neuroscience*. 22(17), 7730-6.
88. Williams B J; Cascieri M A; Chicchi G G; Harrison T; Owens A P; Owen S N; Rupniak N M J; Tattersall D F; Williams A; Swain C J (2002) Spirocyclic NK(1) antagonists II: [4.5]-spiroethers. (2002) *Bioorganic and Medicinal Chemistry Letters*, 12(19), 2719-22.

89. Swain, C. (200) NK1 receptor antagonists. (2002) Editor(s): King, Frank D. Medicinal Chemistry (2nd Edition), 415-427. Publisher: Royal Society of Chemistry, Cambridge.
90. Rupniak, N M. J.; Carlson, E J.; Shephard, S; Bentley, G; Williams, A R.; Hill, A; Swain, C; Mills, S G.; Di Salvo, J; Kilburn, R; Cascieri, M A.; Kurtz, M M.; Tsao, K-L; Gould, S L.; Chicchi, G G. (2003) Comparison of the functional blockade of rat substance P (NK1) receptors by GR205171, RP67580, SR140333 and NKP-608., Neuropharmacology 45(2), 231-241.
91. Raubo, P; Kulagowski, J J.; Swain, C J. (2003) A stereoselective synthesis of (R)-3-aryl-6-phenyl-1-oxa-7-azaspiro[4.5]-decanes. Synlett (13), 2021-2024.
92. Gregory J. Hollingworth, Emma J. Carlson, José L. Castro, Gary G. Chicchi, Natalie Clark, Laura C. Cooper, Olivier Dirat, Jerry Di Salvo, Jason M. Elliott, Ruth Kilburn, Marc M. Kurtz, Wayne Rycroft, F. David Tattersall, Kwei-Lan Tsao and Christopher J. Swain. (2006) Novel lactam NK₁ antagonists with anti-emetic activity. Biorg and Medchem Lett 16, 1197
93. Swain C. J., iBabel, CDK News, vol. 3, issue 1, pages 19-20

PAPERS SUBMITTED FOR CLEARANCE/PUBLICATION

5 publications not yet in public domain

MERCK ABSTRACTS

Posters

Quinuclidine based NK₁ Antagonists, summer Neuropeptide Conference, Martha's Vineyard, June 1993.

External Lectures

Drugs acting on the cholinergic neurotransmission system, Leicester University undergraduate course Nov, 1994, 1995, 1996, 1997, 1998.

Novel 5-HT₃ Antagonists, Trends in Receptor Research, Camerino 1991.

Substance P antagonists, Gordon Conference on Medicinal Chemistry, Colby-Sawyer College, Aug. 1994.

Neurokinin antagonists RSC-SCI, Medicinal Chemistry Summer School, Canterbury, July 1995.

Substance P antagonists, Trends in Medicinal Chemistry, London. September 1995.

Substance P antagonists, Tachykinins '95, Florence October 1995.

Neurokinin Antagonists, Sydney University Oct 1997

Neurokinin Antagonists, Tachykinins '97, Cairnes Oct 1997

Bioorganic and Medchem School, Princeton March 1997

Substance P antagonists, IRBM, July 1997

Neurokinin antagonists RSC-SCI, Medicinal Chemistry Summer School, UMIST, July 1999.

Substance P Antagonists ACS 223rd National Meeting April 2002

Neurokinin antagonists RSC-SCI, Medicinal Chemistry Summer School, Univ Nottingham, July 2003.

Neurokinin antagonists RSC-SCI, Medicinal Chemistry Summer School, Univ Nottingham, July 2005.

PATENTS

1. Kulagowski, Janusz Jozef; Swain, Christopher John; Thomson, Christopher George; Raubo, Piotr Alpoli. Preparation of spiro-azacyclic derivatives and their use as tachykinin antagonists. PCT Int. Appl. WO 9854187 A1
2. Curtis, Neil Roy; Elliott, Jason Matthew; Hollingworth, Gregory John; Jackson, Philips Stephen; Kulagowski, Janusz Jozef; Seward, Eileen Mary; Swain, Christopher John; Williams, Brian John. Spiro-azacyclic derivatives and their use as therapeutic agents. PCT Int. Appl., 73 pp. WO 9849170 A1 981105.
3. Harrison, Timothy; Swain, Christopher John. Preparation of 3,3-disubstituted piperidines for treating the conditions associated with an excess of tachykinins. U.S., 17 pp US 5807865 A 980915
4. Maccoss, Malcolm; Mills, Sander G.; Harrison, Timothy; Swain, Christopher John. Preparation of 5-aryl-5-heterocyclylpropylpiperidin-2-ones as modulators of chemokine receptor activity. PCT Int. Appl., 92 pp. . WO 9831364 A1 980723.
5. Haworth, Karen Elizabeth; Seward, Eileen Mary; Swain, Christopher John. Preparation of azaoxaspiroalkanes and -enes as tachykinin antagonists. PCT Int. Appl., 100 pp. . WO 9813369 A1 980402.
6. Curtis, Neil Roy; Huscroft, Ian Thomas; Kulagowski, Janusz Jozef; Swain, Christopher John. Spiro-piperidine derivatives and their use as therapeutic agents. PCT Int. Appl., 103 pp. . WO 9801450 A1 980115
7. Moseley, Jonathan David; Swain, Christopher John. Spiro-ketal derivatives and their use as therapeutic agents (tachykinin antagonists). PCT Int. Appl., 92 pp. . WO 9730056 A1 970821.
8. Elliott, Jason Matthew; Kelleher, Fintan; Swain, Christopher John. Spiro-ketal derivatives and their use as therapeutic agents (tachykinin antagonists). PCT Int. Appl., 75 pp. . WO 9730055 A1 970821. CAN 127:248119
9. Baker, Raymond; Elliott, Jason; Swain, Christopher John. Preparation of tetrazole moiety-containing benzylaminopyrrolidines and benzylaminopiperidines as tachykinin receptor antagonists. PCT Int. Appl., 51 pp. . WO 9721702 A1 970619.
10. Baker, Raymond; Harrison, Timothy; Swain, Christopher John; Williams, Brian John. Spiro-piperidine derivatives and their use as tachykinin antagonists. PCT Int. Appl., 152 pp. . WO 9719084 A1 970529.
11. Swain, Christopher John; Teall, Martin Richard; Williams, Brian John. Preparation of morpholine derivatives as tachykinin antagonists. PCT Int. Appl., 70 pp. . WO 9718206 A1 970522

12. Moseley, Jonathan David; Swain, Christopher John; Williams, Brian John. Preparation of morpholine N-oxides as tachykinin antagonists. Brit. UK Pat. Appl., 63 pp. CODEN: BAXXDU. GB 2302689 A1 970129.
13. Baker, Raymond; Elliott, Jason; Stevenson, Graeme Irvine; Swain, Christopher John. Preparation of piperidine and morpholine derivatives as tachykinin antagonists. PCT Int. Appl., 66 pp. . WO 9701554 A1 970116.
14. Baker, Raymond; Elliott, Jason; Stevenson, Graeme Irvine; Swain, Christopher John. Preparation of piperidine and morpholine derivatives as tachykinin antagonists. PCT Int. Appl., 72 pp. . WO 9701553 A1 970116.
15. Harrison, Timothy; Owen, Simon Neil; Seward, Eileen Mary; Swain, Christopher John. Preparation of spiroketals as tachykinin antagonists. PCT Int. Appl., 108 pp. . WO 9620197 A1 960704. CAN 125:195668
16. Harrison, Timothy; Owens, Andrew Pate; Swain, Christopher John. Preparation of N-(aminobutynyl)morpholines as tachykinin antagonists. PCT Int. Appl., 78 pp. . WO 9605181 A1 960222.
17. Haworth, Karen Elizabeth; Teall, Martin Richard; Seward, Eileen Mary; Swain, Christopher John. Morpholine derivatives and their use as antagonists of tachykinins. PCT Int. Appl., 44 pp. . WO 9530674 A1 951116.
18. Maccoss, Malcolm; Swain, Christopher John. Preparation of aralkylamino-substituted azacyclic tachykinin antagonists. PCT Int. Appl., 49 pp. . WO 9520575 A1 950803.
19. Baker, Raymond; Harrison, Timothy; Macleod, Angus Murray; Owens, Andrew Pate; Seward, Eileen Mary; Swain, Christopher John; Teall, Martin Richard. Preparation of arylmorpholine derivatives as tachykinin antagonists. PCT Int. Appl., 148 pp. . WO 9518124 A1 950706.
20. Baker, Raymond; Macleod, Angus Murray; Seward, Eileen Mary; Swain, Christopher John. Preparation of aralkoxy and aralkylthio substituted azacyclic compounds as tachykinin antagonists. PCT Int. Appl., 46 pp. . WO 9521819 A1 950817.
21. Baker, Raymond; Swain, Christopher John; Williams, Brian John. Preparation of azacyclic tachykinin receptor antagonists. PCT Int. Appl., 51 pp. . WO 9419323 A1 940901
22. Baker, Raymond; Ladduwahetty, Tamara; Seward, Eileen Mary; Swain, Christopher John. Azacyclic tachykinin antagonists. PCT Int. Appl., 132 pp. . WO 9321181 A1 931028
23. Swain, Christopher John. Azabicyclic tachykinin receptor antagonists. Brit. UK Pat. Appl., 25 pp. CODEN: BAXXDU. GB 2268931 A1 940126.
24. Seward, Eileen Mary; Swain, Christopher John. Preparation of azacyclic compounds as tachykinin antagonists. PCT Int. Appl., 54 pp. . WO 9402461 A1 940203.
25. Swain, Christopher John. Azatricyclic tachykinin antagonists. Brit. UK Pat. Appl., 23 pp. CODEN: BAXXDU. GB 2269170 A1 940202.
26. Ladduwahetty, Tamara; Swain, Christopher J. Azabicyclic compounds as tachykinin antagonists. Eur. Pat. Appl., 21 pp. CODEN: EPXXDW. EP 536817 A1 930414.
27. Baker, Raymond; Harrison, Timothy; Swain, Christopher J.; Williams, Brian J. Preparation of 3-benzyloxy-2-phenylpiperidines and analogs as tachykinin antagonists. Eur. Pat. Appl., 38 pp.

CODEN: EPXXDW. EP 528495 A1 930224.

28. Baker, Raymond; MacLeod, Angus Murray; Merchant, Kevin John; Swain, Christopher John. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy. PCT Int. Appl., 83 pp. WO 9301169 A2 930121. CAN 119:117105
29. Baker, Raymond; Swain, Christopher J.; Teall, Martin R.; Williams, Brian J. Preparation of benzyloxyazabicycloalkanes as tachykinin antagonists. Eur. Pat. Appl., 16 pp. CODEN: EPXXDW. EP 520555 A1 921230.
30. Swain, Christopher J.; Teall, Martin R.; Williams, Brian J. Preparation of 2-amino-1-benzyloxy-3,3-diphenylpropanes and analogs as tachykinin antagonists. Eur. Pat. Appl., 39 pp. CODEN: EPXXDW. EP 522808 A2 930113.
31. Baker, Raymond; Swain, Christopher; Seward, Eileen M. Preparation of benzyloxyazabicycloalkanes as tachykinin antagonists. Eur. Pat. Appl., 26 pp. CODEN: EPXXDW. EP 499313 A1 920819.
32. Baker, Raymond; Swain, Christopher; Saunders, John. Preparation and formulation of indolyl(imidazolylalkyl)oxazoles, -oxadiazoles, and analogs as S3 antagonists. U.S., 11 pp. CODEN: USXXAM. US 5140034 A 920818.
33. Baker, Raymond; Kneen, Clare O.; Saunders, John; Swain, Christopher. Preparation of spirocyclic compounds incorporating five-membered rings with two heteroatoms, especially spiro[azabicyclooctaneoxazoles], useful as drugs. Eur. Pat. Appl., 38 pp. CODEN: EPXXDW. EP 337547 A1 891018.
34. Owen, Simon Neil; Swain, Christopher John; Williams, Brian John. Preparation of 2(R)-[1-[3,5-bis(trifluoromethyl)phenyl]-2(S)-hydroxyethoxy]-3(S)-(4-fluorophenyl)-4-[(1-methyl-1,2,4-triazol-3-yl)methyl]morpholine for treatment of pain, inflammation, migraine, emesis, postherpetic neuralgia, depression, or anxiety. U.S. (1999), 9 pp
35. Baker, Raymond; Curtis, Neil Roy; Elliott, Jason Matthew; Harrison, Timothy; Hollingworth, Gregory John; Jackson, Philip Stephen; Kulagowski, Janusz Jozef; Rupniak, Nadia Melanie; Seward, Eileen Mary; Swain, Christopher John; Williams, Brian John. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety. U.S. (2000), 14 pp.
36. Baker, Raymond; Curtis, Neil Roy; Elliott, Jason Matthew; Harrison, Timothy; Hollingworth, Gregory John; Jackson, Philip Stephen; Kulagowski, Janusz Jozef; Rupniak, Nadia Melanie; Seward, Eileen May; Swain, Christopher John; Williams, Brian John. Use of NK-1 receptor antagonists for treating schizophrenic disorders. U.S. (2000), 14 pp., Cont.-in-part of U.S. Ser. No. 980,930,
37. Owen, Simon Neil; Seward, Eileen Mary; Swain, Christopher John; Williams, Brian John. Preparation of novel substituted tetrahydropyrans as neurokinin 1 (NK-1) receptor antagonists. PCT Int. Appl. (2000), 149 pp
38. Castro Pineiro, Jose Luis; Dinnell, Kevin; Elliott, Jason Matthew; Hollingworth, Gregory John; Shaw, Duncan Edward; Swain, Christopher John. Synthesis of aryl-amido-cyclohexane derivatives and their use as NK-1 receptor antagonists. PCT Int. Appl. (2001), 199 pp. CODEN: PIXXD2 WO 2001087838 A1
39. MacLeod, Angus Murray; Swain, Christopher John; Van Niel, Monique Bodil. Preparation of 1-piperidinylpropan-2-ols as antidepressants and anxiolytics. Brit. UK Pat. Appl. (2000), 56 pp. CODEN: BAXXDU GB 2347423

40. Owen, Simon Neil; Seward, Eileen Mary; Swain, Christopher John; Williams, Brian John. Preparation of 2-pyranyl ethers as NK1 receptor antagonists. PCT Int. Appl. (2000), 43 pp. CODEN: PIXXD2 WO 2000056728
41. Castro Pineiro, Jose Luis; Dinnell, Kevin; Elliott, Jason Matthew; Hollingworth, Gregory John; Shaw, Duncan Edward; Swain, Christopher John. Preparation of cyclohexane derivatives for therapeutic use in the treatment of disorders, such as depression, anxiety, pain, inflammation, migraine, and vomiting. PCT Int. Appl. (2001), 153 pp. CODEN: PIXXD2 WO 2001087866 A
42. Baker, Raymond; Saunders, John; Swain, Christopher. Five-membered heterocycles as pharmaceuticals. Eur. Pat. Appl., 39 pp. CODEN: EPXXDW. EP 328200 A1 890816 Castro Pineiro, Jose Luis; Owen, Simon Neil; Seward, Eileen Mary; Swain, Christopher John; Williams, Brian John. Preparation of difluorophenyltetrahydropyran derivatives as nk-1 receptor antagonists. PCT Int. Appl. (2002), 30 pp. CODEN: PIXXD2 WO 2002016343 A1
43. Castro Pineiro, Jose Luis; Owen, Simon Neil; Seward, Eileen Mary; Swain, Christopher John; Williams, Brian John. Preparation of tetrahydropyran derivatives as nk-1 receptor antagonists. PCT Int. Appl. (2002), 51 pp. CODEN: PIXXD2 WO 2002016344 A1 20020228
44. Owen, Simon Neil; Swain, Christopher John; Williams, Brian John. Arylmethoxytetrahydrofuran derivatives and their use as NK-1 antagonists. PCT Int. Appl. (2002), 54 pp. CODEN: PIXXD2 WO 2002024673 A1
45. Castro Pineiro, Jose Luis; Raubo, Piotr Antoni; Swain, Christopher John. Preparation of [(phenylethoxy)tetrahydropyranyl]piperidinecarboxylates and analogs as neurokinin NK-1 receptor antagonists. PCT Int. Appl. (2002), 69 pp.
46. Castro Pineiro, Jose Luis; Dinnell, Kevin; Elliott, Jason Matthew; Hollingworth, Gregory John; Shaw, Duncan Edward; Swain, Christopher John. Preparation of gem-disubstituted cyclohexane-containing azetidinones, pyrrolidinones and piperidinones as neurokinin 1 receptor antagonists and their use as therapeutic agents. PCT Int. Appl. (2002), 58 pp. CODEN: PIXXD2 WO 2002102372 A1 20021227
47. Dirat, Olivier; Elliott, Jason Matthew; Huscroft, Ian Thomas; Jelley, Richard Alexander; Kulagowski, Janusz Jozef; Raubo, Piotr Antoni; Shaw, Duncan Edward; Sternfeld, Francine; Swain, Christopher John. Preparation of phenylethoxytetrahydropyranylmethyloxaazaspirodecanes and related compounds as tachykinin antagonists. PCT Int. Appl. (2004), 140 pp.

A further 8 applications not in public domain.